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Purpose: To examine patient-reported outcome (PRO) in a selected group of Swedish patients about to receive
anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular edema (DME).
Material and methods: In this cross-sectional study, 59 patients with diabetes mellitus, who regularly visited
the outpatient eye-clinics, were included. Sociodemographic and clinical data were collected and the patients
completed PRO measures before starting anti-VEGF treatment. PRO measures assessed eye-speciﬁc outcomes
(NEI-VFQ-25) and generic health-related quality of life (SF-36).
Results: The participants consisted of 30 men and 29 women (mean age, 68.5 years); 54 (92%) patients had
type 2 diabetes; 5 (9%) patients hadmoderate or severe visual impairment; 28 (47%) were classiﬁed as having
mild visual impairment. Some of the patients reported overall problems in their daily lives, such as with social
relationships, as well as problems with impaired sight as a result of reduced distance vision.
Conclusions: Further studies are needed to investigate PRO factors related to low perceived general health in
this patient population. It is important to increase our understanding of such underlying mechanisms to
promote improvements in the quality of patient care.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetesmellitus is a lifelongdiseaseaffectingan increasingnumberof
people worldwide (International Diabetes Federation, n.d.). Diabetes is
generally divided into type 1 and type 2 diabetes mellitus: the former is
characterized by beta cell destruction, the latter by insulin resistance and
impaired beta cell function. The common denominator is high blood
glucose (DCCT and EDIC: The Diabetes Control and Complications Trial
and Follow-up Study; Stratton, Kohner, Aldington, & Turner, 2001). Late
complications of diabetes include macrovascular and microvascular
disease. Diabetic microvascular complications in the eye – retinopathy –
occur in both type 1 and type 2 diabetes, and they affect the blood vessels
of the retina (DCCT and EDIC: The Diabetes Control and Complicationsre no conﬂicts of interest.
460 71 45 (mobile); fax: +46
c. This is an open access article underTrial and Follow-up Study; Lutty, 2013; Stratton et al., 2001; UK
Prospective Diabetes Study (UKPDS), 1991). Diabetic microvascular
disease of the macula may induce macular edema, which can severely
reduce visual acuity. The prevalence of diabetic macular edema (DME)
ranges from 2.1% to 7.5% in different patient populations (Heintz, 2012;
Hirai, Knudtson, Klein, & Klein, 2008; Raymond et al., 2009; Varma et al.,
2014); diabetic retinopathy is a major cause of severely impaired vision
and blindness globally (Bourne et al., 2014). Among DME patients, visual
impairment is regarded as the most feared late diabetic complication
(Janzen Claude, Hadjistavropoulos, & Friesen, 2014). In recent years,
patient-reported outcomemeasures have acquired greater importance in
capturingpatients’ thoughts and feelings.Among thedimensions included
in patient-reported outcome measures are quality of life, health-related
quality of life, and visual function (Denniston, Kyte, Calvert, & Burr, 2014;
Leksell, Wikblad, & Sandberg, 2005; Weldring & Smith, 2013; Wikblad,
Smide, & Leksell, 2014).
As deﬁned in the Early Treatment Diabetic Retinopathy Study
(ETDRS), (Photocoagulation fordiabeticmacular edema:EarlyTreatmentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Left: male individual, aged 67 years, moderate diabetic retinopathy and diabetes macular edema in the right eye; visual acuity ETDRS 70, corresponding to logMAR 0.4. Right:
healthy fundus and macular OCT in 51-year-old female individual.
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Retinopathy Study research group, 1985) clinically signiﬁcant DME is
sight threatening and requires treatment. Fig. 1 shows a fundus and
optical coherence tomography (OCT) with moderate DME compared
with a healthy fundus andmacular OCT. Laser therapywas established in
1985 and has been shown to reduce the risk of severe vision loss by 50%
(Photocoagulation for diabetic macular edema: Early Treatment Diabetic
Retinopathy Study Report number 1. Early Treatment Diabetic Retinop-
athy Study research group, 1985). However, improvement in visual
acuity by laser treatment is limited (Beck et al., 2009). In 2010, itwasﬁrst
reported that repeated intravitreal administration of ranibizumab, an
inhibitor of vascular endothelial growth factor (VEGF), reduces macular
edemaand improves visual acuity inpatientswith visual impairment as a
result of DME (Massin et al., 2010). Other studies using ranibizumab
(Elman, Elman, Aiello, Beck, & Bressler, 2010; Mitchell et al., 2011;
Nguyen et al., 2012) and another inhibitor of VEGF, aﬂibercept (Do,
Nguyen, Boyer, & Schmidt-Erfurth, 2012), have reported similarﬁndings.
A strong association between visual acuity and patient-reported visual
function independent of the severity of retinopathy and other compli-
cations has been found in diabetic patients (Gonder et al., 2014; Hirai,
Tielsch, Klein, & Klein, 2011; Klein, Moss, Klein, Gutierrez, & Mangione,
2001; Trento et al., 2013; Tsilimbaris, Kontadakis, Tsika, Papageorgiou, &
Charoniti, 2013). The improvement in visual acuity inducedby anti-VEGF
treatment for DME observed in pivotal clinical trials has been found to be
associated with enhanced visual function measured with the National
Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) (Bressler et
al., 2014; Korobelnik et al., 2014; Mitchell, Bressler, Tolley, et al., 2013),
especially if the better-seeing eye has been treated (Bressler et al., 2014;
Mitchell et al., 2013).
In Sweden, intravitreal administration of anti-VEGF drugs for
sight-threatening DME is now part of routine clinical care. Previously,
health-related quality of life and visual function were investigated in
Swedishdiabeticpatientsparticipating ina screeningprogramfordiabetic
retinopathy (Heintz,Wirehn, Peebo, Rosenqvist, & Levin, 2012). However,
information is limited about patient-reportedhealth-related quality of life
and visual function in patients with DME about to undergo intravitreal
anti-VEGF treatment for visual impairment.
1.1. Aims of this cross-sectional study
• To describe visual function (NEI VFQ-25) and patient-reported
health-related quality of life (36-item short-form health survey[SF-36]) in a cohort of Swedish diabetic patients about to
undergo anti-VEGF treatment for visual impairment due to DME
in routine clinical care.
• To explore the relationship between patient-reported visual
function and health-related quality of life with regard to visual
impairment, degree of retinopathy, and whether treatment was
planned for the better- or worse-seeing eye.
• To analyze the correlation between the two different objective
measurements of visual acuity.
2. Methods
2.1. Subjects
This study enrolled participants with diabetes of either sex aged
18 years or older who were about to receive treatment with
ranibizumab (Lucentis) for visual impairment due to DME. The
patients had to be Swedish speaking and have the cognitive ability to
complete the surveys and participate in an interview. Enrollment took
place from May 2012 to February 2014 at two county hospitals in
Sweden. We excluded patients who had previously been treated with
intravitreal anti-VEGF for DME. All patients who met the inclusion
criteria were asked about study participation.
2.2. Ethical considerations
This study was approved by the Regional Ethical Review Board in
Uppsala, Sweden, andwas conducted in accordancewith the tenets of the
Declaration of Helsinki. The participants obtained written and verbal
information related to the study. All the participants gave their written
informed consent. The data were labeled using code numbers and were
handled with respect for the participants’ privacy and integrity.
2.3. Clinical assessment
Social background characteristics, including age, weight, sex, level of
education, marital status, and information about employment or
retirement status, were collected from all patients by interview. Data
about the duration of diabetes, diabetes treatment, and late diabetic
complications were obtained from medical records. Late complications
included retinopathy, nephropathy, neuropathy, and macrovascular
disease (previous stroke, transitory ischemic attack, or myocardial
Table 1
Sociodemographics and clinical characteristics of the subjects.
Variable Mean ± SD range N
Age, years 68.5 (±10.0) 45–86 59
45–60 11
61–70 23
71–80 18
N80 7
Gender 59
Male/female 30/29
Education level 59
Elementary school 33
Middle school 18
University 8
Marital status 56
Cohabiting (married) 36
Living alone (divorced/widow/widower) 20
Employment 59
Retired 39
Working 16
Unemployed/sick leave 4
Type of diabetes 59
Type 1 5
Type 2 54
Hba1C (mmol/mol) 67.68 (±15.91) 39–120 56
Duration of diabetes 17 (±10) 0–49 59
Length 167 (±9.29) 150–186
Weight 83 (±24) 47–159
Systolic blood pressure 151 (±24) 100–240
Diastolic blood pressure 82 (±11) 60–110
Diabetes treatment 59
Insulin/insulin pump (22/1) 23
Tablets 14
Insulin and tablets 22
Other medical treatment 59
Blood pressure treatment 48
Lipid treatment 36
Anticoagulantia 36
Hemodialysis 1
Number of diabetes late complications 59
1 19
2 28
≥3 12
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(Lilja et al., 2013) level was obtained from electronic patient records. The
patients also speciﬁed their number of late diabetic complications.
The initial eye examination included measurement of best-cor-
rected visual acuity with the ETDRS or Snellen chart, slit-lamp
examination of the anterior segment, intraocular pressure measure-
ment, fundus biomicroscopy, andmeasurement of retinal thickness by
OCT (Topcon Corporation, Tokyo, Japan).
We performed grading of diabetic retinopathy with indirect ophthal-
moscopy as follows: mild non-proliferative diabetic retinopathy (NPDR);
moderate NPDR; severe NPDR; or proliferative diabetic retinopathy
(Wilkinsonet al., 2003). Clinically, signiﬁcant diabeticmacular edemawas
deﬁned according to ETDRS (Photocoagulation for diabetic macular
edema: Early Treatment Diabetic Retinopathy Study Report number 1.
Early Treatment Diabetic Retinopathy Study research group, 1985). Based
on the patient’s better-seeing eye, visual impairmentwas categorized into
three groups: normal vision logarithm of minimum angle of resolution
(logMAR) ≤0.10; mild visual impairment logMAR 0.20–0.50; and
moderate/severe visual impairment logMAR≥0.60. Thedegreeof diabetes
retinopathy was categorized based on the worse-seeing eye as mild/
moderate, severe, or proliferative.
All the patients received two questionnaires – NEI VFQ-25 and
SF-36 – at baseline. The patients could choose either to answer the
questionnaires at the clinic or to take them home, answer them there,
and return the completed forms by mail to the clinic.
2.4. Questionnaires
The eye-speciﬁc questionnaire, NEI VFQ-25, reﬂects the respondent’s
self-reported visual function in subscales: general health; general vision;
ocular pain; near activities; distance activities; driving; color vision;
peripheral vision and social functioning; role difﬁculties; and dependency
(Mangione et al., 2001; Mangione et al., 1998). The instrument has been
validated for Swedish-speaking patients in the EMGT-study (Eriksson,
Sjöstrand, & Kroksmark, 2008). We employed the manual for scoring
(Mangione, 2000). The subscale scores were 0–100, where a higher NEI
VFQ-25 score indicates better visual functioning.
The SF-36 (Maruish) measures eight dimensions of health-related
quality of life: physical function; role functioning (physical limita-
tions); bodily pain; general health; vitality; social function; role
functioning (emotional limitations); andmental health. The SF-36 has
been validated and translated into Swedish (Sullivan, Karlsson, &
Ware, 1995). This survey was designed for self-administration (Ware
& Sherbourne, 1992).
2.5. Methods for measuring visual acuity
We measured visual acuity either according to the ETDRS using the
ETDRS letter chart at a distance of 2 m or using the Snellen chart at 5 m.
ETDRS visual acuity (number of letters) was measured with the eyes
planned for anti-VEGF treatment.Wemeasured visual acuity for the other
eyes using the Snellen chart. Snellen values were converted to logMAR
with the formula logMAR = –log (decimal acuity) (Holladay, 1997).
2.6. Data analysis
SPSS (version 22, SPSS Inc., Chicago, IL, USA) was used for statistical
analyses. We followed themanual for NEI VFQ-25 in calculating the scale
conversions and subscale scoreswith 11 vision-related constructs plus an
additional single-item general health question. The driving subscale had a
high rate ofmissing data (17/59, 29%), andwe calculated the results for 42
patients, according to themanual (Mangione, 2000). A p value b0.05 was
considered statistically signiﬁcant. After verifying that they were
equivalent, we merged the patients from the two eye clinics into a
single cohort.Mean scores, standard deviation (SD), and range were calculated
for the subscales in SF-36 and NEI VFQ-25. We used analysis of
variance (ANOVA) to examine the relationship between NEI VFQ 25
and SF-36 with regard to visual impairment, degree of retinopathy,
and whether treatment was planned for the better- or worse-seeing
eye. We employed the Spearman correlation analysis to analyze the
correlation between ETDRS and logMAR values. Tukey’s post hoc test
was used to determine subgroup differences.
3. Results
3.1. Study subjects
We enrolled 63 patients in this study. Two patients declined
participation, and four patients discontinued participation after
inclusion. In all, 59 patients completed the study.
3.2. Patient demographics and characteristics
Sociodemographics and clinical characteristics of the included partic-
ipants appear in Table 1. The study sample was equally distributed
regarding sex. The mean age was 68.5 (±10.0) years. Over half the
participants had completed elementary school, and eight had attained
university-level education.Mostof theparticipants (64%)were cohabiting.
The majority of participants (66%) had retired. Of the patients, 54 (92%)
had type 2diabetes. Regarding late diabetic complications, includingDME,
40 (68%) patients had two or more late complications (Table 1).
Table 2
Eye history and eye planned for treatment.
Retinopathy degree (worse seeing eye) 58⁎
Mild/moderate 29
Severe 15
Proliferative 14
Visual impairment 59
Normal 26
Mild 28
Moderate/severe 5
Eye planned for treatment 59
Better seeing eye 10
Worse seeing eye 36
Neither better nor worse seeing eye 7
Both eyes 6
Able to drive/able to read 44/57
⁎ One patient was not possible to rate.
Table 4
Scores for each subscale of NEI VFQ-25 and SF-36.
Subscale Mean SD Range Missing
NEI VFQ-25 questionnaire
General health 35.65 22.04 0–100 5
General vision 60.71 18.28 10–100 3
Ocular pain 84.21 20.80 25–100 2
Near activities 66.23 21.56 25–100 2
Distance activities 73.54 24.62 0–100 2
Social functioning 87.50 19.66 12.5–100 2
Mental health 76.54 20.87 0–100 2
Role difﬁculties 78.07 25.14 0–100 2
Dependency 93.48 18.12 0–100 4
Driving 72.02 37.02 0–100 17
Color vision 91.18 19.41 6–100 3
Peripheral vision 77.68 21.16 25–100 3
Composite score 78.12 16.72 18.60–97.61 2
SF-36 questionnaire
Physical functioning 67.42 27.15 5–100 0
Role Physical 71.30 34.10 0–100 5
Bodily pain 70.16 29.55 0–100 2
General Health 56.55 22.14 5–97 2
Vitality 61.40 20.46 12.5–100 6
Social functioning 84.15 22.80 12.5–100 3
Role emotional 88.73 22.32 0–100 5
Mental health 77.45 17.11 30–100 2
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61% of the patients, treatment was planned for the worse-seeing eye
(WSE) (Table 2).
The mean ETDRS score in the eye planned for treatment was 63.9 ±
13.2; it was 73.3 ± 12.8 in the eye for which no treatment was planned.
Almost 30% of the patients had previously undergone treatment with
panretinal laser photocoagulation in the eye planned for DME treatment.
Over 60% of patients had previously received laser treatment for DME in
the eye planned for treatment (Table 3).
3.3. Visual function (NEI VFQ-25) in the cohort with DME
With NEI VFQ-25, the subjects showed the lowest score for the
subscale of general health (mean 35.65 ± 22.04) and the highest for
dependency (mean 93.48 ± 18.12) (Table 4).
3.4. Self-reported health-relatedquality of life (SF-36) in the cohortwithDME
For SF-36, the subjects gave the lowest score in the subscale of
general health (mean 56.55 ± 22.14) and the highest for the subscale
of role emotional (mean 88.73 ± 22.32) (Table 4).
3.5. Subgroup analysis regarding visual functioning and health-related
quality of life (NEI VFQ-25 and SF-36)
3.5.1. Degree of visual impairment
With the NEI VFQ-25, signiﬁcant relationships were found
between the degree of visual impairment and number of subscales
(Table 5). Tukey’s post hoc tests demonstrated a signiﬁcant difference
between the participants with normal vision compared with
participants that were moderate or severe in eight of the subscales.
For SF-36, ANOVA showed no signiﬁcant differences in degree of
visual impairment, level of retinopathy, or which eye was planned for
treatment in any of the SF-36 domains (data not shown).Table 3
Eye history.
Eye planned for treatment
Mean ± SD range
Visual acuity (ETDRS) 63.9 (±13.2) 21–84
Visual acuity (logMar) 0.44 (±0.26) 0.05–1.30
Central retinal thickness (OCT) 396 (±129) 183–836
Preavious panretinal laser
photocoagulation
Preavious laser for DME
Irisrubeosis
Glaucoma
Previous cataract surgery3.5.2. Planned treatment
Regarding which eye was planned for treatment, we found a
signiﬁcant relationship for NEI VFQ-25 and the subscales of general
vision, social functioning, role difﬁculties, and driving. Table 5
indicates that the participants for whom treatment was planned for
the better-seeing eye (BSE) rated signiﬁcantly lower than participants
in whom treatment was planned for the WSE (post-hoc Tukey).
3.5.3. Level of retinopathy
The level of retinopathy showed no signiﬁcant relation to any of
the NEI VFQ-25 subscales (data not shown).
3.6. Analysis of correlation between two objective measurements of
visual acuity
The Spearman correlation between ETDRS and Snellen logMAR values
showed a signiﬁcant negative correlation (r = −0.98, p = 0.000).
4. Discussion
This study found that diabetic patients with visual impairment as a
result of DME about to undergo anti-VEGF treatment had a very low score
for the VFQ-25 subscale of general health. Although the majority of the
patients also have undergone laser treatment, they scored low general
health as pointed out in a previous study (Turkoglu et al., 2015).
In most of the VFQ-25 subscales, patients with moderate or severe
visual impairment had lower scores than patients with normal vision.
Furthermore, our results indicate that patients for whom treatmentEye not planned for treatment
N Mean ± SD range N
65 73.3 (±12.8) 59–85 4
65 0.26 (±0.35) 0–1.30 50
61 277 (±61) 194–480 40
19 11
40 23
1 0
3 4
21 14
Table 5
ANOVA and post hoc analysis for NEI VFQ-25 with regard to degree of visual impairment and planned treatment.
N Mean SD Tukey post hoc
Visual Impairment
General Health normal 25 40.00 22.82
mild 25 32.00 21.73
moderate/severe 4 31.25 23.94
Total 54 35.65 22.46
F-value, p-value 0.096, 0.411 ns
General Vision normal 25 66.4 18
mild 27 57.78 17.83
moderate/severe 4 45.00 10.00
Total 56 60.71 18.28
F-value, p-value 3.29, 0.045 ns
Ocular Pain normal 25 89.00 16.66
mild 28 82.14 22.93
moderate/severe 4 68.75 23.94
Total 57 84.21 20.80
F-value, p-value 1.972, 0.149 n
Near Activities normal 25 73.00 16.89
mild 28 63.69 22.48
moderate/severe 4 41.67 24.53
Total 57 66.23 21.57
F-value, p-value 4.53, 0.0015 0.016 normal
N moderate/severe
4.9652 57.7015
Distance Activities normal 25 82.67 15.62
mild 28 70.83 25.61
moderate/severe 4 35.42 27.53
Total 57 73.54 24.62
F-value, p-value 8.465, 0.001 0.001 normal
N moderate/severe
18.8604 75.6396
0.01 mild
N moderate/severe
7.2376 63.5957
Social Functioning normal 24 96.35 11.35
mild 28 84.38 18.20
moderate/severe 4 56.25 33.07
Total 56 87.5 19.66
F-value, p-value 10.575, 0.000 0.036 normal N mild 0.6242 23.3341
0.000 normal
N moderate/severe
18.0591 62.1493
0.008 mild
N moderate/severe
6.306 49.944
Mental Health normal 25 79 22.81
mild 28 77.46 17.29
moderate/severe 4 54.69 24.14
Total 57 76.54 20.87
F-value, p-value 2.523, 0.09 ns
Role Difﬁculties normal 25 85.50 16.01
mild 28 78.13 23.48
moderate/severe 4 31.25 37.50
Total 57 78.07 25.14
F-value, p-value 10.851, 0.000 0.000 normal
N moderate/severe
26.1853 82.3147
0.000 mild
N moderate/severe
19.0184 74.7316
Dependency normal 24 97.57 6.26
mild 27 92.90 17.10
moderate/severe 4 72.92 48.77
Total 55 93.48 18.12
F-value, p-value 3.496, 0.038 0.029 normal
N moderate/severe
2.0611 47.2444
Driving normal 20 88.75 9.85
mild 19 65.79 42.46
moderate/severe 3 0 0
Total 42 72.02 37.02
F-value, p-value 12.45, 0.000 0.000 normal
N moderate/severe
44.0199 133.4801
0.003 mild
N moderate/severe
20.9061 110.6728
Color Vision 24 89.8333 22.22 22.22
28 95.5357 9.75 10.21
4 68.75 37.5 37.50
56 91.1786 19.41 19.85
F-value, p-value 3.779, 0.029 0.024 mild
N moderate/severe
2.9403 50.6311
Peripheral Vision normal 24 84.38 19.24
mild 28 76.79 24.47
(continued on next page)
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Table 5 (continued)
N Mean SD Tukey post hoc
moderate/severe 4 43.75 23.94
Total 56 77.68 24.16
F-value, p-value 5.726, 0.006 0.004 normal
N moderate/severe
11.5639 69.6861
0.021 mild
N moderate/severe
4.2727 61.7987
Composite score normal 25 83.95 11.76
mild 28 77.10 15.62
moderate/severe 4 48.93 24.71
Total 57 78.13 16.92
F-value, p-value 9.86, 0.000 0.000 normal
N moderate/severe
15.8844 54.1573
0.002 mild
N moderate/severe
9.173 47.162
Planned treatment
General Health better seeing eye 9 36.11 18.16
worse seeing eye 34 36.03 24.76
neither 7 28.57 17.25
both eyes 4 43.75 12.50
Total 54 35.65 22.04
F-value, p-value 0.386, 0.763 ns
General Vision better seeing eye 9 46.67 20.00
worse seeing eye 34 64.71 17.10
neither 7 62.86 17.99
both eyes 6 56.67 15.06
Total 56 60.71 18.28
F-value, p-value 4.217, 0.010 0.004 BSE N WSE −35.4495 − .6290
Ocular Pain better seeing eye 10 73.75 26.65
worse seeing eye 34 84.56 20.19
neither 7 92.86 9.83
both eyes 6 89.58 20.03
Total 57 84.21 20.80
F-value, p-value 0.993, 0.404 Ns
Near Activities better seeing eye 10 55.83 19.27
worse seeing eye 34 70.59 21.15
neither 7 63.10 21.97
both eyes 6 62.50 25.14
Total 57 66.23 21.56
F-value, p-value 1.171, 0.330 ns
Distance Activities better seeing eye 10 65.00 26.29
worse seeing eye 34 80.02 20.94
neither 7 58.93 30.47
both eyes 6 68.06 27.72
Total 57 73.54 24.62
F-value, p-value 2.184, 0.101 ns
Social Functioning better seeing eye 10 76.25 23.16157
worse seeing eye 33 95.08 10.79795
neither 7 76.79 18.29813
both eyes 6 77.08 34.83592
Total 56 87.50 19.65613
F-value, p-value 4.809, 0.005 0.026 BSE N WSE 1.6895 35.9620
Mental Health better seeing eye 10 68.75 20.20
worse seeing eye 34 78.86 21.49
neither 7 81.25 11.41
both eyes 6 70.83 26.71
Total 57 76.54 20.87
F-value, p-value 0.759, 0.522 Ns
Role Difﬁculties better seeing eye 10 57.50 31.29
worse seeing eye 34 84.56 16.87
neither 7 83.93 18.70
both eyes 6 68.75 41.65
Total 57 78.07 25.15
F-value, p-value 4.191, 0.010 0.012 BSE N WSE −49.3697 −4.7480
Dependency better seeing eye 10 86.67 25.22
worse seeing eye 32 96.61 7.88
neither 7 97.61 6.30
both eyes 6 83.33 40.82
Total 55 93.48 18.12
F-value, p-value 1.686, 0.182 ns
Driving better seeing eye 7 55.36 51.97
worse seeing eye 24 88.54 10.37
neither 6 52.08 43.60094
both eyes 5 40.00 54.77226
Total 42 72.02 37.02026
F-value, p-value 5.352, 0.004 0.021 WSE N both 5.5951 91.4883
Color Vision better seeing eye 10 90.00 17.48
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Table 5 (continued)
N Mean SD Tukey post hoc
worse seeing eye 33 91.85 19.58
neither 7 92.86 12.20
both eyes 6 87.50 30.62
Total 56 91.18 19.41
F-value, p-value 0.162, 0.921 ns
Peripheral Vision better seeing eye 10 67.50 31.30
worse seeing eye 33 81.82 20.03
neither 7 71.43 26.73
both eyes 6 79.17 29.23
Total 56 77.68 24.16
F-value, p-value 0.806, 0.497 ns
Composite Score better seeing eye 10 68.20 19.87
worse seeing eye 34 82.56 12.30
neither 7 76.17 16.75
both eyes 6 71.82 27.85
Total 57 78.13 16.92
F-value, p-value 2.435, 0.076 ns
1189T. Granström et al. / Journal of Diabetes and Its Complications 29 (2015) 1183–1190was planned for the BSE scored lower on general vision, social
function, and role difﬁculties than patients for whom treatment was
planned for theWSE. By contrast, no differences were foundwhen the
cohort was divided into subgroups according to level of retinopathy.
This means that patients with visual impairment due to DME have
reduced general health, but the diagnosis of DME or diabetes
retinopathy in itself has no or a limited effect on general health.
Regarding health-related quality of life measured using the SF-36, we
found no differences when the sample was divided into subgroups
according to degree of visual impairment, level of retinopathy, or treated
eye. This indicates that the SF-36 may not be capable of capturing all
relevant vision-related aspects of health-related quality of life.
In this study, we recruited patients from routine clinical care at two
medium-sized county hospitals. Overall, the patient demographics,
clinical characteristics, and visual functioning in the present clinical
study were comparable with baseline characteristics in large pivotal
clinical trials with ranibizumab for DME (Bressler et al., 2014; Mitchell
et al., 2011). In the present study, we found a wide range in several
baseline variables, such as age, glycosylated hemoglobin, weight, and
blood pressure, which suggests heterogeneity among the included
patients. Our ﬁndings appear to indicate that the diabetic population
with DME in need of anti-VEGF treatment in the real-world setting is less
homogeneous with regard to background characteristics than patients
recruited in a clinical trial. The patient sample in the present study was
relatively small. However, this study provides valuable information about
patients offered treatment for DME in clinical settings.
The most unexpected result in this study was the low scoring on the
NEI VFQ-25 subscale for general health—both from a clinical viewpoint
and when compared with other similar studies (Trento et al., 2013;
Turkoglu et al., 2015) aswell as in those onpatientswith glaucoma (Kong,
Zhu,Hong,& Sun, 2014) andpatients diagnosedbefore the age of 30 years
(Hirai et al., 2011). One possible explanation is that the majority of
patients in our sample had at least one other diabetes-related complica-
tion inaddition toDME. It iswell knownthat twoormorediabetes-related
late complicationshave an impact ongeneral health (Heintz, 2012; Leksell
et al., 2005; Rubin & Peyrot, 1999; Wikblad et al., 2014). In particular,
neuropathy in combination with retinopathy may lead to a substantial
negative impact on general health. In the present study, respondents
reported that they had sensory loss, which is suggestive of neuropathy in
the hands or feet. However, one weakness with this study is the lack of a
control group, which does not allow a direct comparison with a
comparable patient cohort or sample.
VFQ-25 analysis showed that there was a relationship with visual
impairment in most of the subscales. It seems reasonable to suppose that
visual impairment affected those subscales. This is conﬁrmation of the
fact that from the patient’s perspective, vision has a huge impact on daily
life. Furthermore, the particular eye treated played an especially signiﬁcant
role for general vision, social functioning, role difﬁculties, and driving. Forthe majority of patients in our sample, treatment was planned for the BSE
withvisual impairment. The third subgroupanalysis on level of retinopathy
found no differences among any of the subscales in the NEI VFQ-25. This
indicates that the diagnosis of diabetes retinopathy in itself has no or a
limitedeffect onapatient’s reportedoutcome in termsof visual functioning.
Heintz et al. (2012) arrived at similar results in their thesis. For that reason,
it is important that patients regularlyundergo fundusphotographybecause
even severe retinopathy can occur without symptoms.
Our analysis of the two different objective methods for measuring
visual acuity– theETDRSandSnellencharts– showedastrongcorrelation.
Measurement of visual acuity according to the ETDRS gives an accurate
value, especially if visual acuity is reduced (Falkenstein et al., 2008), but it
is more time consuming than standard acuity testing using the Snellen
chart. In real-world settings, as was the case in the present study, the
ETDRS chart is generally preferable for diagnosis and follow-upof the eyes
subject to anti-VEGF treatment.
In conclusion, this study found that patients with diabetes who were
going to undergo anti-VEGF treatment for visual impairment due to DME
gave a low rating for their general health as measured with the visual
function-speciﬁcNEIVFQ-25. It is important to increase theawarenessof this
ﬁnding among healthcare professionals dealing with this group of patients.
This study has relatively small sample size due to the number of
patients that received the treatment. But the value of the study is that it is
implemented in real-world settings, and the results of the study can
therefore be generalized for the group of Swedish patients with diabetes
about to undergo anti-VEGF treatment for sight-threatening DME.
More research isneeded toexamine theunderlying reasons for this low
score in general health. It is crucial to increase our understanding of the
underlying mechanisms so as to promote improvements in the treatment
of this group of patients. Further, it is now important to follow patient
cohorts or samples while on treatment to monitor potential changes in
SF-36 and VFQ-25 scores induced by anti-VEGF treatment for DME.
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